您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报 (医学版) ›› 2018, Vol. 56 ›› Issue (5): 52-57.doi: 10.6040/j.issn.1671-7554.0.2017.1137

• • 上一篇    下一篇

玉米须多糖对糖尿病小鼠肝损伤及糖代谢的影响

张众一1,张淇1,揭毅1,周思1,武海艳1,臧颖2,潘敬学3,伍宇平3,那晓东4   

  1. 中山大学中山医学院 1.临床医学系;2.生理学教研室;3.医学实验教学中心机能学实验室;4.病理生理学教研室, 广东 广州 510080
  • 收稿日期:2017-11-13 发布日期:2022-09-27
  • 通讯作者: 那晓东. E-mail:naxd@mail.sysu.edu.cn
  • 基金资助:
    国家自然科学基金面上项目(81371228);中央高校基本科研业务费专项资金(16ykjc02);中山大学本科教改项目(16370005,18822607)

Effects of stigma maydis polysaccharides on liver protection and glycometabolism in diabetic mice

ZHANG Zhongyi1, ZHANG Qi1, JIE Yi1, ZHOU Si1, WU Haiyan1, ZANG Ying2, PAN Jingxue3, WU Yuping3, NA Xiaodong4   

  1. 1. Department of Clinical Medicine;
    2. Department of Physiology;
    3. Functional Laboratory of Experimental Center for Basic Medical Teaching;
    4. Department of Pathophysiology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, Guangdong, China
  • Received:2017-11-13 Published:2022-09-27

PDF (PC)

267

摘要： 目的 探讨玉米须多糖对糖尿病小鼠模型的护肝降糖作用及其对肝糖代谢的影响。 方法 将50只小鼠分为空白对照组(NC组)、高血糖对照组(HG组)、二甲双胍组(MET组)、25 mg/kg玉米须多糖组(SMP25组)及50 mg/kg玉米须多糖组(SMP50组),每组10只。采用腹腔注射四氧嘧啶方法制备糖尿病小鼠模型,利用血糖测试仪测定小鼠空腹血糖(FPG)浓度,通过比色法测定小鼠肝糖原含量,通过药物性肝损伤病理组织学评分系统(DILI-PSS)评估肝损伤情况。 结果 与HG组相比,SMP50组小鼠的FPG降低34.3%(P<0.001)、肝糖原含量提高321.5%(P<0.001);与MET组相比,SMP25、SMP50组小鼠肝糖元含量均升高(P<0.001),且肝细胞水肿和脂肪性变均减轻(P<0.001);SMP50组的降糖护肝作用优于SMP25组(P<0.001)。 结论 玉米须多糖可降低糖尿病小鼠的FPG,促进肝糖元的合成,并可减轻造模药物及高血糖引起的肝损害,有望成为糖尿病患者护肝降糖辅助治疗选择。

关键词: 玉米须多糖, 糖尿病, 肝糖元, 肝损伤

Abstract: Objective To investigate the effects of stigma maydis polysaccharides on glycometabolism and liver protection in diabetic mice. Methods Fifty mice were divided into normal control group(NC group), hyperglycemia control group(HG group), metformin group(MET group), 25 mg/kg polysaccharide derived from stigma maydis group(SMP25 group), and 50 mg/kg polysaccharide derived from stigma maydis group(SMP50 group), ten in each group. The diabetic mice models were prepared by peritoneal injection of alloxan, the fasting plasma glucose(FPG)were measured by a blood glucose tester, the content of liver glycogen in mice were measured by colorimetry, and the liver injury was evaluated by drug-induced liver injury-pathological scroring system(DILI-PSS). Results Compared with 山 东 大 学 学 报 (医 学 版)56卷5期 -张众一,等.玉米须多糖对糖尿病小鼠肝损伤及糖代谢的影响 \=-HG group, FPG value was reduced by 34.3%(P<0.001), the content of glycogen was increased by 321.5% in SMP50 group; compared with MET group, the contents of glycogen were increased(P<0.001), and hepatocyte edema and hepatic steatosis were reduced(P<0.001)in SMP25 and SMP50 groups; the effects of blood sugar control and liver protection in SMP50 group is better than those in SMP25 group(P<0.001). Conclusion Polysaccharides derived from stigma maydis can significantly reduce the FPG concentration, promote the synthesis of glycogen, reduce the liver injury caused by modeling drugs and hyperglycemia in diabetic mice, and is expected to provide a effective adjuvant treatment option for diabetics.

Key words: Polysaccharide derived from stigma maydis, Diabetes, Glycogen, Liver injury

中图分类号: 

  • TS201.1
[1] Lagani V, Koumakis L, Chiarugi F, et al. A systematic review of predictive risk models for diabetes complications based on large scale clinical studies[J]. J Diabetes Complications, 2013, 27(4): 407-413.
[2] Pyram R, Kansara A, Banerji MA, et al. Chronic kidney disease and diabetes[J]. Maturitas, 2012, 71(2): 94-103.
[3] Forbes JM, Cooper ME. Mechanisms of diabetic complications[J]. Physiol Rev, 2013, 93(1): 137-188.
[4] Hazlehurst JM, Woods C, Marjot T, et al. Non-alcoholic fatty liver disease and diabetes[J]. Metabolism, 2016, 65(8): 1096-1108.
[5] Ahmadieh H, Azar ST. Liver disease and diabetes: association, pathophysiology, and management[J]. Diabetes Res Clin Pract, 2014, 104(1): 53-62.
[6] Targher G, Byrne CD. Clinical review: nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications[J]. J Clin Endocrinol Metab, 2013, 98(2): 483-495.
[7] 宋烨,王明彦,宋成武,等.玉米须水煎液对1型、2型糖尿病小鼠降血糖活性的研究[J].时珍国医国药, 2013, 24(11): 2627-2630. SONG Ye, WANG Mingyan, SONG Chengwu, et al. Hypoglycemic effect of corn silk decoction in alloxan-induced type 1 and type 2 diabetic mice[J]. Lishizhen Medicine and Materia Medica Research, 2013, 24(11): 2627-2630.
[8] 朱亮,石海春,罗强,等.玉米须多糖的提取、组成和生物活性研究[J].四川大学学报(自然科学版), 2013, 50(3): 631-637. ZHU Liang, SHI Haichun, LUO Qiang, et al. Purification, composition and biological activity of the polysaccharide isolated from corn silk[J]. Journal of Sichuan University(Natural Science Edition), 2013, 50(3): 631-637.
[9] 陈琛,徐华影.玉米须抗糖尿病活性成分的分离及其作用机制研究[J].中成药, 2015, 37(7): 1492-1497. CHEN Chen, XU Huaying. Separation of anti-diabetic constituents from corn stigma and their mechanism of action[J]. Chinese Traditional Patent Medicine, 2015, 37(7): 1492-1497.
[10] 徐丹鸿,林道鹏.超声波法提取酸浆宿萼多糖条件的优化[J].保鲜与加工, 2015, 15(4): 43-46. XU Danhong, LIN Daopeng. Optimization of ultrasonic extraction of polysaccharides in persistent calyx of physalis alkekengi[J]. Storage and Process, 2015, 15(4): 43-46.
[11] 骆静方,魏巍,乔楠,等.鞣花酸对四氧嘧啶糖尿病小鼠的影响[J].中国糖尿病杂志, 2016, 24(7): 649-651. LUO Jingfang, WEI Wei, QIAO Nan, et al. Effect of ellagic acid on alloxan-induced diabetes in mice[J]. Chin J Diabetes, 2016, 24(7): 649-651.
[12] Garcia-Cortes M, Lucena MI, Pachkoria K, et al. Evaluation of naranjo adverse drug reactions probability scale in causality assessment of druginduced liver injury[J]. Aliment Pharmacol Ther, 2008, 27(9): 780-789.
[13] Penckofer S, Doyle T, Byrn M, et al. State of the science: depression and type 2 diabetes[J]. West J Nurs Res, 2014, 36(9): 1158-1182.
[14] Waterfalli M, Musekiwa A, Engel ME, et al. The prevalence of type 2 diabetes mellitus among older people in Africa: a systematic review study protocol[J]. BMJ Open, 2014, 4(6): e004747. doi: 10.1136/bmjopen-2013-004747.
[15] [No authors listed] Summary of revisions: standards of medical care in diabetes-2018[J]. Diabetes Care, 2018, 41(Suppl 1): S4-S6.
[16] Chang CC, Yuan W, Roan HY, et al. The ethyl acetate fraction of corn silk exhibits dual antioxidant and anti-glycation activities and protects insulin-secreting cells from glucotoxicity[J]. BMC Complement Altern Med, 2016, 16(1): 432.
[17] Yang J, Li X, Xue Y, et al. Anti-hepatoma activity and mechanism of corn silk polysaccharides in H22 tumor-bearing mice[J]. Int J Biol Macromol, 2014, 64: 276-280.
[18] 宫春宇,郑喜群,陈泽峰,等.玉米须多糖现状研究[J].江苏农业科学, 2016, 44(3): 4-7. GONG Chunyu, ZHENG Xiqun, CHEN Zefeng, et al. Research progress on polysaccharides from corn silk[J].The Jiangsu Agricultural Sciences, 2016, 44(3): 4-7.
[19] Cha JH, Kim SR, Kang HJ, et al. Corn silk extract improves cholesterol metabolism in C57BL/6J mice fed high-fat diets[J]. Nutr Res Pract, 2016, 10(5): 501-506.
[20] Joel Z, Per-Henrik G. Strategies for diabetes management: using newer oral combination therapies early in the disease[J]. Diabetes Ther, 2016, 7(4): 621-639.
[21] Li W, Yuan G, Pan Y, et al. Network pharmacology studies on the bioactive compounds and action mechanisms of natural products for the treatment of diabetes mellitus: a review[J]. Front Pharmacol, 2017, 2(8): 1-9.
[22] Suzuki A, Brunt EM, Kleiner DE, et al. The use of liver biopsyevanluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury[J]. Hepatology, 2011, 54(3): 931-939.
[23] Ahn JM, Palk YH, Kim SH, et al. Relationship of liver stiffness and controlled attenuation parameter measured by transient elastography with diabetes mellitus in patients with chronic liver disease[J]. J Korean Med Sci, 2014, 29(8): 1113-1119.
[24] Kramer CK, Retnakaran R. Liver enzymes and type 2 diabetes: a complex two-wat relationship[J]. J Diabetes Complications, 2013, 27(4): 301-302.
[25] Garcia-Compean D, Gonzalez-Gonzalez JA, Lavalle-Gonzalez FJ, et al. The treatment of diabetes mellitus of patients with chronic liver disease[J]. Ann Hepatol, 2015, 14(6): 780-788.
[1] 董萍,沈海涛,乔亚琴,路燕. 自噬在APAP肝损伤及肝再生过程中的调控作用[J]. 山东大学学报 (医学版), 2026, 64(5): 42-49.
[2] 吕明阅,孙汉辰,罗清馨,徐朝珂,徐瑞泽,张硕,严鲁宁,胡锡峰,赵青波,朱高培,薛付忠. 硝苯地平和美托洛尔对心脏病的治疗效果[J]. 山东大学学报 (医学版), 2025, 63(9): 1-10.
[3] 孟晓梅,郝亚平,王亮,于晓,唐与晓. 血清Isthmin1、Gremlin2水平与2型糖尿病患者视网膜病变的相关性[J]. 山东大学学报 (医学版), 2025, 63(9): 102-107.
[4] 王梦星,薛付忠,杨帆. 基于多模态交叉注意力机制融合的1型糖尿病血糖浓度预测方法[J]. 山东大学学报 (医学版), 2025, 63(8): 41-50.
[5] 申路佳,逯天威,巩伟明,赵岩松,王淑康,袁中尚. 代谢风险评分在2型糖尿病人群心血管结局预测中的应用[J]. 山东大学学报 (医学版), 2025, 63(8): 69-78.
[6] 陈莹莹,王鲁,胡锡峰,朱高培,薛付忠. 基于贝叶斯网络的2型糖尿病患者并发脑卒中风险预测[J]. 山东大学学报 (医学版), 2025, 63(8): 94-102.
[7] 陈绪军, 何国伟. 着力进一步推进动脉桥在我国冠心病冠脉旁路移植术中的应用[J]. 山东大学学报 (医学版), 2025, 63(5): 1-5.
[8] 卢圣勋,邢亚闯,罗俊辉,刘杰,何厚乐,王志强,张娜. 糖尿病患者冠脉旁路移植手术中动脉桥的研究现状[J]. 山东大学学报 (医学版), 2025, 63(5): 33-39.
[9] 杜学识,倪向敏,梁馨予,白倩,朱文艺,王建. 雌马酚对DN的保护作用及潜在靶点[J]. 山东大学学报 (医学版), 2024, 62(8): 49-58.
[10] 许沛晨,李晓博,庄向华,娄能俊,吕丽,周玲雁,牟亚朋,宋玉文,陈诗鸿. 儿童Alstrom综合征2例并文献复习[J]. 山东大学学报 (医学版), 2024, 62(3): 107-111.
[11] 林晓倩,封茂燕,牟正. 二肽基肽酶-4抑制剂的药学特点及临床应用[J]. 山东大学学报 (医学版), 2024, 62(12): 43-48.
[12] 于丹凤,曹娟,于世佳,杜鲁涛,侯新国. 电化学发光法与液相色谱-串联质谱法评估糖尿病患者维生素D缺乏程度的效能比较与界值确定[J]. 山东大学学报 (医学版), 2023, 61(7): 90-95.
[13] 李金泉,高美芳,闫飞,董明. 136例2型糖尿病患者肌肉痉挛的发生频率及危险因素[J]. 山东大学学报 (医学版), 2023, 61(5): 20-24.
[14] 张天鑫,张婷,黄鑫,韩佳沂,王淑康. 氨基酸与2型糖尿病因果关系的孟德尔随机化分析[J]. 山东大学学报 (医学版), 2023, 61(5): 102-107.
[15] 黄珊,娄能俊,韩晓琳,梁中昊,华梦羽,庄向华,陈诗鸿. 高糖环境下Lipin1对神经元代谢组学的影响[J]. 山东大学学报 (医学版), 2023, 61(2): 1-8.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发